Rhythm Pharmaceuticals Announces Orphan Drug Designation Granted to Setmelanotide for Treatment of Hypothalamic Obesity in Japan
Setmelanotide is a melanocortin-4 receptor (MC4R) agonist designed to treat hyperphagia and obesity. Rhythm is evaluating setmelanotide in a global Phase 3 trial in patients with acquired hypothalamic ...
Expert sheds light on medical breakthroughs in obesity treatment
Unlock the latest advancements in obesity treatment. Expert insights reveal groundbreaking medical breakthroughs and ...
Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target Raised to $66.00 at Needham & Company LLC
Rhythm Pharmaceuticals (NASDAQ:RYTM – Free Report) had its target price increased by Needham & Company LLC from $64.00 to $66 ...
Charles Schwab Investment Management Inc. Acquires 6,384 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)
Charles Schwab Investment Management Inc. grew its holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Free Report) by ...
AZoRobotics on MSN15h
Forget Ozempic—This AI-Found Peptide May Be the Future of Weight Loss
The identification of BRP, an anti-obesity peptide, showcases the transformative role of AI in drug discovery and its ...